P2X7 receptor activation impairs antitumour activity of natural killer cells

被引:8
作者
Baroja-Mazo, Alberto [1 ]
Penin-Franch, Alejandro [1 ]
Lucas-Ruiz, Fernando [1 ]
De Torre-Minguela, Carlos [1 ]
Alarcon-Vila, Cristina [1 ]
Hernandez-Caselles, Trinidad [1 ,2 ]
Pelegrin, Pablo [1 ,2 ]
机构
[1] Univ Clin Hosp Virgen La Arrixaca, Biomed Res Inst Murcia IMIB Pascual Parrilla, Murcia, Spain
[2] Univ Murcia, Fac Med, Dept Biochem & Mol Biol B & Immunol, Murcia, Spain
基金
欧洲研究理事会;
关键词
A438079; ATP; IL-2; natural killer cells; tumour environment; CONCISE GUIDE; DANGER SIGNAL; EXPRESSION; LYMPHOCYTES; INHIBITION; MODULATION; CALCIUM; CANCER;
D O I
10.1111/bph.15951
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and purpose A high number of intratumoural infiltrating natural killer (NK) cells is associated with better survival in several types of cancer, constituting an important first line of defence against tumours. Hypoxia in the core of solid tumours induces cellular stress and ATP release into the extracellular space where it triggers purinergic receptor activation on tumour-associated immune cells. The aim of this study was to assess whether activation of the purinergic receptor P2X7 by extracellular ATP plays a role in the NK cells antitumour activity. Experimental approach We carried out in vitro experiments using purified human NK cells triggered through P2X7 by extracellular ATP. NK cell killing activity against the tumour target cells K562 was studied by means of NK cytotoxicity assays. Likewise, we designed a subcutaneous solid tumour in vivo mouse model. Key results In this study we found that human NK cells, expressing a functional plasma membrane P2X7, acquired an anergic state after ATP treatment, which impaired their antitumour activity and decreased IFN-gamma secretion. This effect was reversed by specific P2X7 antagonists and pretreatment with either IL-2 or IL-15. Furthermore, genetic P2rx7 knockdown resulted in improved control of tumour size by NK cells. In addition, IL-2 therapy restored the ability of NK cells to diminish the size of tumours. Conclusions and implications Our results show that P2X7 activation represents a new mechanism whereby NK cells may lose antitumour effectiveness, opening the possibility of generating modified NK cells lacking P2X7 but with improved antitumour capacity.
引用
收藏
页码:111 / 128
页数:18
相关论文
共 73 条
  • [1] Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth
    Adinolfi, E
    Callegari, MG
    Ferrari, D
    Bolognesi, C
    Minelli, M
    Wieckowski, MR
    Pinton, P
    Rizzuto, R
    Di Virgilio, F
    [J]. MOLECULAR BIOLOGY OF THE CELL, 2005, 16 (07) : 3260 - 3272
  • [2] P2X7 receptor: Death or life?
    Adinolfi E.
    Pizzirani C.
    Idzko M.
    Panther E.
    Norgauer J.
    Di Virgilio F.
    Ferrari D.
    [J]. Purinergic Signalling, 2005, 1 (3) : 219 - 227
  • [3] Accelerated Tumor Progression in Mice Lacking the ATP Receptor P2X7
    Adinolfi, Elena
    Capece, Marina
    Franceschini, Alessia
    Falzoni, Simonetta
    Giuliani, Anna L.
    Rotondo, Alessandra
    Sarti, Alba C.
    Bonora, Massimo
    Syberg, Susanne
    Corigliano, Domenica
    Pinton, Paolo
    Jorgensen, Niklas R.
    Abelli, Luigi
    Emionite, Laura
    Raffaghello, Lizzia
    Pistoia, Vito
    Di Virgilio, Francesco
    [J]. CANCER RESEARCH, 2015, 75 (04) : 635 - 644
  • [4] THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Ion channels
    Alexander, Stephen P. H.
    Mathie, Alistair
    Peters, John A.
    Veale, Emma L.
    Striessnig, Jorg
    Kelly, Eamonn
    Armstrong, Jane F.
    Faccenda, Elena
    Harding, Simon D.
    Pawson, Adam J.
    Southan, Christopher
    Davies, Jamie A.
    Aldrich, Richard W.
    Attali, Bernard
    Baggetta, Austin M.
    Becirovic, Elvir
    Biel, Martin
    Bill, Roslyn M.
    Catterall, William A.
    Conner, Alex C.
    Davies, Paul
    Delling, Markus
    Di Virgilio, Francesco
    Falzoni, Simonetta
    Fenske, Stefanie
    George, Chandy
    Goldstein, Steve A. N.
    Grissmer, Stephan
    Ha, Kotdaji
    Hammelmann, Verena
    Hanukoglu, Israel
    Jarvis, Mike
    Jensen, AndersA
    Kaczmarek, Leonard K.
    Kellenberger, Stephan
    Kennedy, Charles
    King, Brian
    Kitchen, Philip
    Lynch, Joseph W.
    Perez-Reyes, Edward
    Plant, Leigh D.
    Rash, Lachlan
    Ren, Dejian
    Salman, Mootaz M.
    Sivilotti, Lucia G.
    Smart, Trevor G.
    Snutch, Terrance P.
    Tian, Jinbin
    Trimmer, James S.
    Van den Eynde, Charlotte
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2021, 178 : S157 - S245
  • [5] THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets
    Alexander, Stephen P. H.
    Kelly, Eamonn
    Mathie, Alistair
    Peters, John A.
    Veale, Emma L.
    Armstrong, Jane F.
    Faccenda, Elena
    Harding, Simon D.
    Pawson, Adam J.
    Sharman, Joanna L.
    Southan, Christopher
    Buneman, O. Peter
    Cidlowski, John A.
    Christopoulos, Arthur
    Davenport, Anthony P.
    Fabbro, Doriano
    Spedding, Michael
    Striessnig, Joerg
    Davies, Jamie A.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2019, 176 : S1 - S20
  • [6] Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of Pharmacology
    Alexander, Steve P. H.
    Roberts, Richard E.
    Broughton, Brad R. S.
    Sobey, Christopher G.
    George, Christopher H.
    Stanford, S. Clare
    Cirino, Giuseppe
    Docherty, James R.
    Giembycz, Mark A.
    Hoyer, Daniel
    Insel, Paul A.
    Izzo, Angelo A.
    Ji, Yong
    MacEwan, David J.
    Mangum, Jonathan
    Wonnacott, Sue
    Ahluwalia, Amrita
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (03) : 407 - 411
  • [7] Extracellular ATP Activates the NLRP3 Inflammasome and Is an Early Danger Signal of Skin Allograft Rejection
    Amores-Iniesta, Joaquin
    Barbera-Cremades, Maria
    Martinez, Carlos M.
    Pons, Jose A.
    Revilla-Nuin, Beatriz
    Martinez-Alarcon, Laura
    Di Virgilio, Francesco
    Parrilla, Pascual
    Baroja-Mazo, Alberto
    Pelegrin, Pablo
    [J]. CELL REPORTS, 2017, 21 (12): : 3414 - 3426
  • [8] Cytokine therapy reverses NK cell anergy in MHC-deficient tumors
    Ardolino, Michele
    Azimi, Camillia S.
    Iannello, Alexandre
    Trevino, Troy N.
    Horan, Lucas
    Zhang, Lily
    Deng, Weiwen
    Ring, Aaron M.
    Fischer, Suzanne
    Garcia, K. Christopher
    Raulet, David H.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (11) : 4781 - 4794
  • [9] P2X7 receptor expression levels determine lethal effects of a purine based danger signal in T lymphocytes
    Aswad, Fred
    Dennert, Gunther
    [J]. CELLULAR IMMUNOLOGY, 2006, 243 (01) : 58 - 65
  • [10] P2X7 receptor-stimulation causes fever via PGE2 and IL-1β release
    Barbera-Cremades, Maria
    Baroja-Mazo, Alberto
    Gomez, Ana I.
    Machado, Francisco
    Di Virgilio, Francesco
    Pelegrin, Pablo
    [J]. FASEB JOURNAL, 2012, 26 (07) : 2951 - 2962